Global Markets
Novo's (NOVOB DC) Ozempic for Australians is expected to fall from about AUD 300 a month for private patients to a small fraction after Australian patents expire in late 2029 and 2031, according to WA Today
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
